Apigenin for Sleep and NAD+: Does It Hold Up?

There is a yellow pigment in chamomile tea that binds the same receptor as Valium, not loosely, the same molecular site, the same lock and key fit. A flower brewed for centuries as a calming drink turns out under chemical scrutiny to contain a compound with a real key to the brain's off switch. The molecule is called apigenin. Most people had not heard of it five years ago. Today it sits inside the most discussed sleep protocol on the internet alongside magnesium and theanine taken before bed by millions of people. It also sits at the center of one of the largest conversations in longevity science, how to keep cells from running out of NAD, the molecule every cell uses to make energy and repair its own DNA, the one that fades as the body ages.

One pigment, two of the hardest problems in human biology, pulled every step of the way from real laboratory work. How did a molecule almost nobody had heard of five years ago end up at the center of two apparently unrelated branches of biology at once? And what does the science trail behind it actually show? The trail begins in 1990 in a small laboratory in Buenos Aires, Argentina. The group there had set itself a patient and unfashionable task across South America. A handful of plants had been used for generations as folk sedatives brewed into teas taken before sleep, prescribed by grandmothers for nerves.

The question on the bench was simply whether any of those calming reputations had a molecular basis, and if so, what the molecule actually was. They began with passion flower, they broke the plant down chemically fraction by fraction and tested each piece against the receptors in the brain that govern calm. One compound kept binding, a small yellow flavonoid, the same chemical family as the one they would eventually find in chamomile. Four years later, working through Linden, another traditional sedative, they identified a second flavonoid doing the same thing.

A pattern was holding there. In 1995, they turned to chamomile. They broke down its extract the same way and watched one fraction show affinity for the receptor again. When they isolated what was in it, the molecule was apigenin, the yellow pigment that gives the flower its faint bitterness, the same compound that tints parsley and celery. Apigenin was binding the GABA-A receptor, specifically the benzodiazepine site on that receptor. GABA is the brain's main calming chemical, the one that slows neurons down when it's time to rest or needs a break applied, and the GABA A receptor is one of the docking stations it uses to exert those effects.

Benzodiazepines, the class of prescription sedatives that includes Valium and Xanax, work by latching on to that same receptor and making GABA's calming signal stronger. They bind a particular spot on it called the benzodiazepine site. That class of drugs is one of the most widely prescribed in the world, used to treat anxiety, panic attacks, insomnia, and seizures, and to sedate patients before surgery. Apigenin was locking on to that exact spot, competitively with measurable affinity and without sticking to several other receptor systems the team had checked.

A plant brewed for centuries as a calming tea turned out to contain a compound with a real mappable key to the brain's off switch working through the same receptor as one of the most widely prescribed drug classes on Earth. The next question, obviously, was whether any of that translated into people. In 2009, a randomized double-blind placebo controlled trial out of the University of Pennsylvania tested an extract with apigenin as the active ingredient in adults with generalized anxiety disorder. The dose was titrated to symptom response, ranging from roughly 3 milligrams per day at the start to 13 milligrams in patients who needed more.

After eight weeks, the group on apigenin had a significantly greater reduction in anxiety scores compared to the placebo. A few years later, the same group ran a larger and longer follow-up, 179 patients with moderate to severe generalized anxiety disorder, treated for 12 weeks with apigenin at roughly 18 milligrams per day, then the responders randomized to either continue apigenin or switch to placebo for another 26 weeks. The patients who stayed on apigenin had significantly lower anxiety symptoms across the half year that followed than the patients on placebo.

A receptor mechanism mapped in Argentina in 1995 to human trials 15 and 20 years later, finding real reductions in anxiety. Bench to bedside in the most direct sense, the phrase allows. But we'll have to come back to that in a bit. None of that, the receptor, the trials, the bench-to-bedside arc would have been enough on its own to put Apigenin where it is today. What put it there was a second discovery made by a separate group in a separate decade, working on a problem that had nothing to do with sleep. In 2013, a team based at the Mayo Clinic in Rochester was studying metabolic disease.

The molecule at the center of their thinking was NAD Plus. Every cell in the body uses NAD Plus to convert food into energy and to repair its own DNA. NAD Plus falls as the body gets older, measurably across tissues, and a great deal of money since has gone into trying to push it back up. The standard approach is to supply more raw material, the precursor sold as NMN and NR. The Mayo team was looking at the other side of the question. One major reason NAD plus drains away with age is an enzyme called CD38, which steadily breaks NAD down.

Working from a screen of small molecules run in collaboration with Harvard, the Mayo group identified two flavonoids that turned out to be CD38 inhibitors, quercetin and apigenin. In their experiments, apigenin blocked CD38, intracellular NAD plus rose, and when they gave the molecule to mice made obese on a high-fat diet, the animal's NAD plus went up in the liver, and their handling of glucose and fat improved. They also ran the experiment with the CD38 enzyme genetically removed, and the effect on NAD disappeared.

Apigenin was working specifically through CD38, and the molecule's absence ruled the effect out as cleanly as its presence ruled it in. The finding was framed around metabolic syndrome, not aging. That leap would come later made by people building the longevity story, not by the laboratory itself. But the mechanism it described was unusually clean. Instead of pouring more water into the tub, apigenin appeared to slow the drain. Seven years later, the result landed again. A group at Kanazawa Medical University in Japan had been studying diabetic kidney disease.

They had already shown that the kidneys of diabetic rats accumulated CD38 and lost NAD plus. They dosed the animals with apigenin orally at one-fifth the amount the Mayo group had injected, five days a week for four weeks. CD38 came down, the NAD plus to NADH ratio came back up. A different country, a different species, a different organ, a different disease, a different route of administration, and a lower dose. The same exact mechanism. Two threads pulled across three decades by groups working on two unrelated problems.

A patient research program in Buenos Aires that traced a calming reputation through three plants and landed on a specific molecular key to the brain's main braking system, confirmed in human anxiety trials 15 and 20 years later. A separate program started at the Mayo Clinic and independently replicated in Japan that found apigenin doing something completely different, blocking the enzyme that drains NAD plus as the body ages. Two reasons people now take apigenin, each one resting on real laboratory work. It's also worth noticing the one thing every finding has in common, the receptor it finds, the enzyme it blocks.

Every one of those results describes what apigenin does once it's already inside the body, at the target, in the tissue, in the cell doing its work. There is a step that comes before any of that. And it's the step almost nobody talking about apigenin appears to mention, whether the molecule itself ever arrives where these studies say it works. The first thing that doesn't quite fit is also the thing nobody on the consumer side seems to say. None of the human trials of apigenin actually used apigenin. To date, there has never been a single study that has used apigenin in isolation to test its effects or its bioavailability in humans.

The Penn anxiety trial in 2009 used chamomile extract standardized to a known apigenin content. The 2016 follow-up that ran for nearly 40 weeks used a different chamomile preparation, also standardized to its apigenin content. The most recent human trial published in 2025 in a population entirely separate from the anxiety trials used chamomile too. Across every controlled experiment in people, what was tested was the plant calibrated to a known dose of the molecule. What's sold in the capsule is the molecule pulled out of the plant, what we call purified apigenin.

Whether those two things behave the same way in the human body is a question that has never actually been answered. There's also the matter of what happened the one time researchers tested chamomile for sleep specifically. The trial enrolled adults with chronic insomnia ran for 28 days and used the same kind of standardized chamomile extract that produced the anxiety results. On the primary sleep outcomes, there was no significant difference between chamomile and placebo. The receptor mechanism is real. The anxiety result is also real.

The sleep result, when it was finally tested, was not. The dose problem is the next thing to consider and it's bigger. The Mayo experiment that started the NAD Plus story injected mice with 100 milligrams of apigenin per kilogram of body weight every day for a week. The follow-up in Japan gave rats one-fifth of that, 20 milligrams per kilogram by mouth, five days a week. Those are the doses that produce the results everyone has been citing for over a decade. To compare animal doses to human doses, honestly, pharmacologists don't multiply directly, they use a standard species correction, translated that way, the mayo mouse dose corresponds to roughly 570 milligrams in a 70 kilogram adult, and the Japanese rat dose to about 225 milligrams.

A standard apigenin capsule contains 50 milligrams. By that yardstick, the amount of apigenin people are actually taking is far below the amount ever shown in any animal to raise NAD plus or move the markers of cellular aging. There's an additional wrinkle on the high end. A separate safety study in rodents in the same dose range as the Mayo experiment reported liver injury. That doesn't mean a 50 milligram capsule is dangerous. It does mean the dose at which the NAD plus effect was originally shown sits in a range where another laboratory found evidence of harm.

The supplement dose you might be taking isn't producing the toxicity, but it also might not be producing the effect you want. None of that means apigenin doesn't do anything, it means the picture is more specific than the marketing makes it. The strongest evidence apigenin has in human beings is for anxiety. Two controlled trials, one of them long-term, both showing measurable reductions in symptoms, and the dose those trials use between 3 and 18 milligrams of apigenin per day sits below what's in a standard capsule.

That's the one place the dose math comes out in the molecule's favor. If anything, the average supplement contains more than the human evidence has actually tested. Sleep is thinner, the receptor mechanism is again real, but the one trial that specifically tested chamomile for sleep didn't find any effect. A very recent piece of preclinical work centered around sleep was published just this year, and it found that apigenin by itself didn't improve sleep in rodents, it only worked when combined with magnesium. The popular sleep stack may turn out to be doing something, but what the data actually supports is a combination of things, not necessarily the molecule on its own.

NAD plus is thinner still, the mechanism is real and replicated, the doses that produce it are far above anything a person is likely to take. The serious research on apigenin hasn't stopped, but it's heading somewhere different from the consumer story. The largest body of preclinical work on this molecule is surprisingly in cancer, two decades of consistent findings that apigenin selectively damages tumor cells while sparing healthy ones across multiple tumor types in dishes and in animals. The molecule is doing something.

The question of whether the version you can buy delivers any of it remains, for now, unanswered. So should you take it? Well, you can. At the doses people are actually taking, there's no safety signals in humans suggesting harm. The only toxicity data on record comes from animal studies at doses orders of magnitude higher by roots nobody is using outside of a laboratory. Chamomile, the source the molecule comes from, has been consumed in tea form for centuries without incident. None of that proves the supplement is doing what's claimed.

It does suggest it's unlikely to hurt you. Whether you should expect a benefit depends on why you're actually taking it. For anxiety, the human evidence is there, and the dose in a typical capsule meets or exceeds what was tested. The catches at trials use chamomile, not the isolate. For sleep, the human evidence is thin, and the closest preclinical work found that the molecule by itself did not improve sleep. Only the combination with magnesium did. For NAD plus or cellular aging, the supplement dose is roughly four to ten times below the lowest dose ever shown to raise NAD plus in any animal.

Whether anything happens at the dose people are actually taking has never been measured in a human being. The molecule is interesting, the marketing has moved faster than the evidence. What's in the bottle and what's on the bottle remain two very different things. Thank you all so much for joining me in today's episode. Until next time, stay healthy.